Scarica l'app Stockscreener
21.19
3.37%
-0.74
Pre-mercato:
21.54
0.35
+1.65%
Structure Therapeutics Inc Adr Borsa (GPCR) Ultime notizie
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? - Zacks Investment Research
Structure (GPCR) Stock Analysis: Falls -5.00%, Watching $20.03 2026-10-18Volatility Surface - https://www.dars.gov.et/
GPCR Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEarnings Quality Score - www.dars.gov.et
GPCR Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesEPS Miss Report - dars.gov.et
Novo Down 11% in a Month: How Should Investors Approach the Stock Now? - Zacks Investment Research
Structure Therapeutics (GPCR) Trades at $25.54, Sitting at the Midpoint of Its Recent RangeEntry Point Alerts - https://www.siam.in/
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity? - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57FRAMA Signal - https://www.dars.gov.et/
Structure Therapeutics (GPCR) Slides 5.23% to $33.23, Pulling Back Toward Key Support at $31.57Bull Flag - https://www.siam.in/
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1? - Zacks Investment Research
Structure Therapeutics (NasdaqGM:GPCR) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com India
Structure Therapeutics (GPCR) CMO sells shares under preset plan - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 4 Structure Therapeutics Inc ADR For: 22 September By Investing.com - Investing.com UK
Structure Therapeutics Inc.American Depositary Shares (Nasdaq:GPCR) Price Chart - The Chronicle-Journal
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Structure Therapeutics at Cantor conference: oral obesity push advances By Investing.com - Investing.com Canada
Structure Therapeutics at Cantor conference: oral obesity push advances - Investing.com
Structure Therapeutics Advances ACCG-2671 with 3.3% Weight Loss; Aleniglipron Hits 16.2% Reduction (NASDAQ: GPCR) - Kalkine Media
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data - investing.com
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Structure Therapeutics (GPCR) Shares Slide After Obesity Drug Tr - GuruFocus
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - theglobeandmail.com
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - Stock Titan
Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit - The Globe and Mail
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Eastern Progress
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseMomentum ETF - dars.gov.et
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - Eastern Progress
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure (GPCR) Watch: Finishes 6.67% Down at $50.52 in the Current Update; Range Check: Support at $47.99 and Resistance at $53.05 Frame the Range at the CloseComposite Profile - www.dars.gov.et
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Warning Signal - dars.gov.et
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionRevenue Guidance Update - careplusvn.com
Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest SessionNegative Surprise Momentum - dars.gov.et
0.58%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):